Translational Development Acquisition Corp.
NASDAQ Capital MarketTotal Valuation
Translational Development Acquisition Corp. carries a market capitalization of 235.51M, placing it among publicly traded companies globally. Its enterprise value stands at 232.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 235.51M |
| Enterprise Value | 232.26M |
Share Statistics
Translational Development Acquisition Corp. currently has 21.91M shares outstanding.
| Shares Outstanding | 21.91M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Translational Development Acquisition Corp. trades at a trailing price-to-earnings ratio of 37.31.
| PE Ratio | 37.31 |
| PS Ratio | N/A |
| PB Ratio | 1.31 |
| P/TBV Ratio | 1.31 |
| P/FCF Ratio | -339.87 |
| P/OCF Ratio | -339.87 |
Financial Position
Translational Development Acquisition Corp. maintains a current ratio of 0.09, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.09 |
| Quick Ratio | 0.03 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | -0.57 |
| Interest Coverage | N/A |
Financial Efficiency
Translational Development Acquisition Corp. posts a return on equity of 3.58 and a return on invested capital of -0.51.
| Return on Equity (ROE) | 3.58 |
| Return on Assets (ROA) | 3.45 |
| Return on Invested Capital (ROIC) | -0.51 |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Translational Development Acquisition Corp.'s stock has gained approximately 5.49558% over the past 52 weeks. The 50-day moving average sits at 10.64, while the 200-day moving average is 10.49.
| Beta (5Y) | N/A |
| 52-Week Price Change | 5.49558% |
| 50-Day Moving Average | 10.64 |
| 200-Day Moving Average | 10.49 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -878,291.00, while operating income came in at -878,291.00.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -878,291.00 |
| Pretax Income | 6.21M |
| Net Income | 6.21M |
| EBITDA | -878,291.00 |
| EBIT | -878,291.00 |
| Earnings Per Share (EPS) | 0.28 |
Balance Sheet
Translational Development Acquisition Corp. holds 24,630.00 in cash and equivalents against 500,000.00 in total debt, resulting in a net debt position of 475,370.00. Total book value stands at 176.45M, with working capital of -785,769.00 providing operational flexibility.
| Cash & Cash Equivalents | 24,630.00 |
| Total Debt | 500,000.00 |
| Net Debt | 475,370.00 |
| Equity (Book Value) | 176.45M |
| Book Value Per Share | 8.05 |
| Working Capital | -785,769.00 |
Cash Flow
Translational Development Acquisition Corp. produced -681,970.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -681,970.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -681,970.00 |
| FCF Per Share | -0.03 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.22 |
| FCF Yield | -0.29 |
Scores
Translational Development Acquisition Corp. posts an Altman Z-Score of 20.09, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 20.09 |